Profile data is unavailable for this security.
About the company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-40.33m
- Incorporated2004
- Employees20.00
- LocationEledon Pharmaceuticals Inc19900 Macarthur Blvd Ste 550IRVINE 92612-8426United StatesUSA
- Phone+1 (949) 238-8090
- Fax+1 (302) 655-5049
- Websitehttps://eledon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Modular Medical Inc | 0.00 | -16.76m | 46.48m | 37.00 | -- | 8.31 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 46.96m | 49.00 | -- | 2.52 | -- | 4.81 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Movano Inc | 0.00 | -29.28m | 47.59m | 30.00 | -- | 7.85 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Journey Medical Corp | 79.18m | -3.85m | 48.76m | 58.00 | -- | 3.32 | -- | 0.6158 | -0.3502 | -0.3502 | 4.19 | 1.05 | 0.8701 | 2.19 | 3.65 | 1,365,190.00 | -4.23 | -- | -10.51 | -- | 66.33 | -- | -4.87 | -- | 1.10 | 0.6863 | 0.4641 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 49.79m | 29.00 | -- | 3.96 | -- | 902.40 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 50.12m | 20.00 | -- | 0.5863 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -5.34m | 50.46m | 4.00 | -- | 1.36 | -- | -- | -0.3704 | -0.3704 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -13.19 | -27.78 | -13.49 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 50.62m | 729.00 | -- | 0.4053 | -- | 0.2936 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Checkpoint Therapeutics Inc | 103.00k | -51.85m | 50.67m | 23.00 | -- | -- | -- | 491.99 | -2.93 | -2.93 | 0.0055 | -0.4703 | 0.011 | -- | -- | 4,478.26 | -555.46 | -142.43 | -- | -342.79 | -- | -- | -50,336.89 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Avrobio Inc | 0.00 | 12.16m | 53.16m | 13.00 | 4.30 | 0.5585 | 4.16 | -- | 0.2756 | 0.2756 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | 11.86 | -45.22 | 13.10 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 53.81m | 5.00 | -- | 4.09 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 4.33m | 17.88% |
| Armistice Capital LLCas of 31 Dec 2023 | 2.19m | 9.05% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 695.42k | 2.87% |
| Woodline Partners LPas of 31 Dec 2023 | 689.34k | 2.85% |
| Ensign Peak Advisors, Inc.as of 31 Dec 2023 | 443.00k | 1.83% |
| Geode Capital Management LLCas of 31 Dec 2023 | 176.04k | 0.73% |
| CM Management LLCas of 31 Dec 2023 | 140.00k | 0.58% |
| Next Edge Capital Corp.as of 31 Dec 2023 | 90.00k | 0.37% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 86.32k | 0.36% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 69.17k | 0.29% |
